U.S. Beverage Stock News

In recent months, Air Products and Chemicals has been the focus of intensive analyst coverage as it reassesses its valuation while continuing large-scale investments in blue and green hydrogen and other industrial gas projects. This mix of cautious analyst sentiment and ongoing hydrogen megaproject initiatives highlights how Air Products is trying to balance stable industrial gas cash flows with an expanding role in the clean energy transition. Against this backdrop, we’ll explore how Air...

Tenaya Therapeutics (TNYA) is back in focus after updating investors on its heart disease gene therapy programs, outlining 2026 clinical milestones alongside a recent US$60 million capital raise that extends its cash runway. See our latest analysis for Tenaya Therapeutics. At a recent share price of US$0.72, Tenaya’s 1 day share price return of 1.95% follows a 90 day share price return decline of 57.39% and a 1 year total shareholder return decline of 44.07%. This suggests that near term...

In early January 2026, Viking and the PGA TOUR announced a multi-year marketing partnership running through 2030 that names Viking the Official Cruise Line of the PGA TOUR and PGA TOUR Champions, with extensive brand campaigns across the TOUR’s media and digital platforms. This alignment ties Viking’s brand to a global, golf-focused audience, potentially broadening its reach among higher-spending leisure travelers who closely follow PGA TOUR events. Next, we’ll examine how Viking’s new PGA...

In recent months, Philip Morris International has highlighted rapid growth in its smoke-free portfolio, especially Zyn nicotine pouches in the U.S., while advancing Iqos heated tobacco products and extending Zyn branding through an expanded Scuderia Ferrari HP Formula 1 partnership. At the same time, the company has been promoting a broader vision that links its push toward a predominantly smoke-free portfolio by 2030 with investments in human cognition, workforce capabilities and...

Earnings and buybacks draw fresh attention to Acuity (AYI) Acuity (AYI) is back on investors’ radar after first quarter results showing sales of US$1,143.7 million and net income of US$120.5 million, alongside continued share repurchases under its long running buyback program. See our latest analysis for Acuity. Despite solid first quarter earnings and steady buybacks, Acuity’s recent share price performance has been weak, with a 30 day share price return of a 15.16% decline and a year to...

Chewy, Inc. recently disclosed that Chief Technology Officer Satish Mehta plans to retire on February 6, 2026, and the company will begin searching for his successor. At the same time, Chewy has drawn increased attention from institutional investors such as Viking Global Investors, highlighting confidence in its subscription-heavy autoship model. We’ll now examine how Chewy’s leadership transition and focus on its autoship-driven subscription model shape the company’s broader investment...

In recent days, APi Group has attracted renewed attention after several analysts issued more positive ratings and highlighted its strong projected earnings growth and improving cash flow trends. This cluster of upbeat assessments not only underscores shifting perceptions of APi Group’s business quality, but also encourages investors to revisit assumptions about its business mix, capital allocation, and risk profile. Next, we’ll examine how this stronger analyst sentiment around APi Group’s...

Recent commentary around Alexandria Real Estate Equities (ARE) has shifted toward its role as a life science campus owner rather than a generic office REIT, as sector conditions and leasing activity gradually stabilize. See our latest analysis for Alexandria Real Estate Equities. Recent price action has been strong in the short term, with a 1 month share price return of 20.22% and a year to date share price return of 19.36%, although the 1 year total shareholder return of 38.17% and 5 year...

Earlier this week, Canaccord Genuity reiterated its positive view on Clover Health, pointing to the company’s technology-first care model, solid membership growth to about 153,000, rising revenues, and sustained adjusted EBITDA profitability as reasons for confidence in its progress toward profitability. The endorsement underscores how Clover Health’s combination of strong member retention and operational efficiencies is becoming central to its evolving business and financial profile. Next,...

Wingstop recently introduced a limited-time Hot Honey Trio across its US restaurants and digital channels, while Wingstop and PopUp Bagels launched a short-run Lemon Pepper Schmear, extending the brand’s signature flavors into breakfast and game-day occasions. Together with the reinstatement of a Chief Operating Officer role to oversee global operations, these flavor innovations highlight Wingstop’s focus on operational discipline and brand-led customer engagement. We’ll now examine how the...

If you are wondering whether Coupang's current share price offers good value or just reflects hype, you are not alone. This article is built to help you make sense of that question. Coupang's share price closed at US$20.24, with returns of a 2.6% decline over 7 days, a 9.7% decline over 30 days, a 13.4% decline year to date and a 9.0% decline over the last year, while the 3 year return sits at 25.9%. Recent coverage of Coupang has focused on its position as a major e commerce and logistics...

In recent months, VSE Corporation reported solid quarterly results alongside long-term revenue growth and wider operating margins, reflecting improved operational efficiency. An interesting angle is that this profitability progress has come even as heavy reinvestment has kept free cash flow margins under pressure. Next, we’ll examine how this combination of stronger operating margins and reinvestment-driven cash flow strain shapes VSE’s investment narrative today. We've found 13 US stocks...

If you are wondering whether Dynex Capital's current share price lines up with its underlying worth, you are not alone. The stock recently closed at US$14.37, with reported returns of 2.2% over 7 days, 3.2% over 30 days, 2.1% year to date, 33.3% over 1 year, 51.6% over 3 years and 43.4% over 5 years, which may influence how investors think about both growth potential and risk. Recent news coverage around Dynex Capital has focused on its position within the diversified financials space and...

Earlier in January 2026, Alnylam Pharmaceuticals issued full-year 2026 guidance, projecting combined net product revenue of US$4.90 billion to US$5.30 billion, implying very large growth versus 2025 at the mid-point. This guidance signals management’s confidence in the commercial traction of its existing therapies and the scalability of its product portfolio. Next, we will examine how this very large step-up in expected 2026 net product revenue shapes Alnylam’s broader investment...

The RealReal has introduced its Athena system to validate goods submitted for resale, aiming to make authentication faster and more reliable. The rollout focuses on improving trust in the platform’s luxury resale offerings and streamlining how items move through its operations. This update is relevant for investors following NasdaqGS:REAL as it affects authentication efficiency and the customer experience. The RealReal, listed as NasdaqGS:REAL, is putting more attention on how it...

Ocular Therapeutix, Inc. recently announced that David W. Robinson, a veteran biopharmaceutical commercial leader with deep ophthalmology experience, will join as Global Chief Commercial Officer, reporting to CEO Pravin U. Dugel, MD, to lead the company’s global commercial efforts. Investors may focus on Robinson’s prior role in launching EYLEA and his recent global ophthalmology leadership at Merck as Ocular prepares for the potential commercialization of AXPAXLI for wet age-related macular...

Banc of California reported past fourth-quarter 2025 results that exceeded analyst expectations, with net interest income of US$251.36 million and net income of US$77.39 million, while also completing a buyback of 13,648,429 shares for US$185.49 million under its March 2025 authorization. Management emphasized double-digit loan and deposit growth, disciplined expense control, and stable credit quality, underscoring an emphasis on profitable, balance-sheet-focused growth. Next, we’ll examine...

GXO Logistics (GXO) has just been named to Fortune’s list of the World’s Most Admired Companies for the first time, a recognition that has sharpened investor attention on the stock and its recent trading move. See our latest analysis for GXO Logistics. The Fortune recognition comes as GXO’s share price has been relatively firm, with a 1 day share price return of 3.22% lifting the stock to US$56.82 and a 30 day share price return of 6.09%. Its 1 year total shareholder return of 26.01%...

California American Water is building an advanced treatment plant to meet updated state standards and expanding aquifer storage and recovery projects. The company is scaling up sustainable water storage initiatives to improve long term supply reliability. In Pennsylvania, American Water Works is encouraging voluntary water use reductions in response to wider drought conditions. For investors watching American Water Works Company (NYSE:AWK), these moves highlight how a regulated utility is...

If you are wondering whether Vistance Networks at US$18.06 is still offering value after a strong run, or if you are late to the story, this breakdown will help you frame that question clearly. The share price has pulled back with a 5.1% decline over the last 7 days and a 1.7% decline over 30 days, even though the 1 year return sits at 208.2% and the 3 year return at 130.4%. Recent coverage has focused on Vistance Networks as a high growth tech name on the Nasdaq and on how its sharp 1 year...

Recent performance snapshot for Denali Therapeutics (DNLI) Denali Therapeutics (DNLI) has drawn fresh attention after recent trading, with the stock closing at US$18.60 and showing mixed return figures over the past year, month, and past 3 months. Short term performance includes a 6.1% move over the past day and a 1.8% change over the past week. The past 3 months show a 17.1% return, and the month reflects a 6.5% gain. See our latest analysis for Denali Therapeutics. While the recent 1 day...

Toast (NYSE:TOST) is rolling out an expanded AI powered platform aimed at retailers beyond its core restaurant base. The update introduces tools for catalog management, invoice scanning, integrated labeling, and simplified digital advertising for more complex retail operations. This shift marks a move toward positioning Toast as a broader retail operating system rather than a restaurant only point of sale provider. For you as an investor, this move matters because Toast is repositioning...

Earlier this week, USA Rare Earth announced that its Less Common Metals Europe subsidiary will build a 3,750-metric-ton-per-year rare earth metal and alloy facility in Lacq, France, backed by French government subsidies covering up to 45% of equipment costs and up to €130 million in real estate support. This project, alongside a co-located oxide processing plant, would create Europe’s first integrated rare earth metal-making platform and further diversify Western supply chains away from...

Recent bullish sentiment from Wall Street has pushed Darling Ingredients (DAR) back into focus, as several research firms reiterated positive views on the stock and raised their expectations for where shares could trade. See our latest analysis for Darling Ingredients. The recent analyst optimism has arrived alongside a sharp pickup in momentum, with a 30-day share price return of 19.87% and a 90-day share price return of 20.05% helping lift the latest share price to $41.62. This comes even...